Michael Terrence  Gibbs net worth and biography

Michael Gibbs Biography and Net Worth

General Counsel of T2 Biosystems
Michael Gibbs joined T2 Biosystems in December 2014 and is the Vice President and General Counsel. Prior to joining T2 Biosystems, Mr. Gibbs was General Counsel for Keystone Dental, Inc., a medical device company in Burlington, MA, from 2011 until 2014. From 2003 to 2011, Mr. Gibbs was a corporate attorney with the law firm Bingham McCutchen LLP (now Morgan Lewis & Bockius) in Boston, MA. Prior to working at Bingham McCutchen, he was an officer in the United States Marine Corps and departed with the rank of Major. Mr. Gibbs has a B.S. from Syracuse University and J.D. from Boston College Law School.

What is Michael Terrence Gibbs' net worth?

The estimated net worth of Michael Terrence Gibbs is at least $1,178.92 as of March 28th, 2023. Mr. Gibbs owns 6,612 shares of T2 Biosystems stock worth more than $1,179 as of September 28th. This net worth estimate does not reflect any other investments that Mr. Gibbs may own. Additionally, Mr. Gibbs receives a salary of $487,330.00 as General Counsel at T2 Biosystems. Learn More about Michael Terrence Gibbs' net worth.

How old is Michael Terrence Gibbs?

Mr. Gibbs is currently 52 years old. There are 6 older executives and no younger executives at T2 Biosystems. The oldest executive at T2 Biosystems is Mr. John M. Sprague CPA, Chief Financial Officer, who is 65 years old. Learn More on Michael Terrence Gibbs' age.

What is Michael Terrence Gibbs' salary?

As the General Counsel of T2 Biosystems, Inc., Mr. Gibbs earns $487,330.00 per year. The highest earning executive at T2 Biosystems is Mr. John J. Sperzel III, B.Sc., Pres, CEO & Chairman, who commands a salary of $865,500.00 per year. Learn More on Michael Terrence Gibbs' salary.

How do I contact Michael Terrence Gibbs?

The corporate mailing address for Mr. Gibbs and other T2 Biosystems executives is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. T2 Biosystems can also be reached via phone at (781) 761-4646 and via email at [email protected]. Learn More on Michael Terrence Gibbs' contact information.

Has Michael Terrence Gibbs been buying or selling shares of T2 Biosystems?

Michael Terrence Gibbs has not been actively trading shares of T2 Biosystems within the last three months. Most recently, Michael Terrence Gibbs sold 239 shares of the business's stock in a transaction on Tuesday, March 28th. The shares were sold at an average price of $0.48, for a transaction totalling $114.72. Following the completion of the sale, the general counsel now directly owns 6,612 shares of the company's stock, valued at $3,173.76. Learn More on Michael Terrence Gibbs' trading history.

Who are T2 Biosystems' active insiders?

T2 Biosystems' insider roster includes Michael Gibbs (General Counsel), Adrian Jones (Director), and John McDonough (Director). Learn More on T2 Biosystems' active insiders.

Are insiders buying or selling shares of T2 Biosystems?

During the last twelve months, insiders at the medical equipment provider sold shares 11 times. They sold a total of 17,006,649 shares worth more than $5,823,159.03. The most recent insider tranaction occured on September, 25th when Major Shareholder Group L.P. Cr sold 250,000 shares worth more than $62,500.00. Insiders at T2 Biosystems own 0.1% of the company. Learn More about insider trades at T2 Biosystems.

Information on this page was last updated on 9/25/2023.

Michael Terrence Gibbs Insider Trading History at T2 Biosystems

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/28/2023Sell239$0.48$114.726,612View SEC Filing Icon  
2/28/2023Sell1,585$0.59$935.156,517View SEC Filing Icon  
2/22/2023Sell2,145$0.65$1,394.255,188View SEC Filing Icon  
4/7/2022Buy10,000$0.49$4,900.00152,350View SEC Filing Icon  
3/25/2021Sell8,758$1.56$13,662.4882,014View SEC Filing Icon  
2/23/2021Sell7,280$2.06$14,996.80View SEC Filing Icon  
2/11/2019Sell3,005$3.36$10,096.8060,262View SEC Filing Icon  
2/1/2019Sell2,759$3.43$9,463.37View SEC Filing Icon  
6/6/2017Buy1,000$3.51$3,510.00View SEC Filing Icon  
See Full Table

Michael Terrence Gibbs Buying and Selling Activity at T2 Biosystems

This chart shows Michael Terrence Gibbs's buying and selling at T2 Biosystems by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

T2 Biosystems Company Overview

T2 Biosystems logo
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria panel, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat panel for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris panel to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme panel, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Read More

Today's Range

Now: $0.18
Low: $0.15
High: $0.18

50 Day Range

MA: $0.30
Low: $0.09
High: $0.59

2 Week Range

Now: $0.18
Low: $0.05
High: $5.72


97,554,828 shs

Average Volume

49,186,039 shs

Market Capitalization

$59.48 million

P/E Ratio


Dividend Yield



[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Get the name of the company here >>>